TLSA
Closed
Tiziana Life Sciences Ltd
0.82
0.00 (0.00%)
Last Update: 06 Sep 2024 23:00:00
Yesterday: 0.82
Day's Range: 0.77 - 0.8689
Send
sign up or login to leave a comment!
When Written:
1.02
Tiziana Life Sciences Ltd is a UK-based biotechnology company that focuses on the development of novel therapies for the treatment of cancer and autoimmune diseases. The company's lead product candidate, Foralumab, is a fully human monoclonal antibody that targets the CD3 receptor on T-cells, which plays a crucial role in the regulation of the immune system. Foralumab is being developed for the treatment of a range of autoimmune diseases, including Crohn's disease, multiple sclerosis, and lupus. Tiziana Life Sciences is also developing a range of other product candidates, including TZLS-501, a novel oral formulation of Foralumab, and TZLS-201, a novel therapy for the treatment of hepatocellular carcinoma. The company was founded in 2013 and is headquartered in London, UK.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!